On March 30, 2015, CMS released three guidance documents detailing the policies that will govern FDA-approved biosimilars under the Medicare Part B and Part D benefits, and how such products will be treated under the Medicaid Drug Rebate Program.  Click here for CMS’s MLN Matters (SE1509) Questions and Answers about Biosimilar Products under the Medicare Part B Program; here for CMS’s Part D Sponsor’s Memorandum regarding Part D Requirements for Biosimilar Follow-on Biological Products; and here for CMS’s Medicaid Drug Rebate Program Notice (Release No. 92) For Participating Drug Manufacturers addressing biosimilars.